Published in Drug Des Devel Ther on September 26, 2014
Investigational reverse transcriptase inhibitors for the treatment of HIV. Expert Opin Investig Drugs (2015) 0.78
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA (2008) 11.72
Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA (2012) 8.94
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Adverse effects of antiretroviral therapy. Lancet (2000) 4.84
Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother (2000) 3.54
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet (2001) 1.87
Efavirenz. Drugs (1998) 1.67
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother (1993) 1.62
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS (2013) 1.49
Clinical pharmacokinetics and pharmacodynamics of etravirine. Clin Pharmacokinet (2009) 1.34
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. Curr Opin Pharmacol (2004) 1.21
Nonlinear pharmacokinetics: clinical Implications. Clin Pharmacokinet (1991) 1.06
Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. Expert Opin Investig Drugs (2009) 0.97
Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. Antivir Ther (2009) 0.90
Population pharmacokinetic analysis to recommend the optimal dose of udenafil in patients with mild and moderate hepatic impairment. Br J Clin Pharmacol (2016) 0.77
Prediction of serum theophylline concentrations and cytochrome P450 1A2 activity by analyzing urinary metabolites in preterm infants. Br J Clin Pharmacol (2016) 0.75
Pharmacokinetics and safety of a single dose of the novel necrosis inhibitor LC28-0126 in healthy male subjects. Br J Clin Pharmacol (2016) 0.75
Indoxyl sulfate (IS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep (2017) 0.75
Identification of ω- or (ω-1)-hydroxylated medium-chain acylcarnitines as novel urinary biomarkers for CYP3A activity. Clin Pharmacol Ther (2017) 0.75